Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Organovo Holdings (NQ: ONVO ) 0.4700 +0.0113 (+2.46%) Streaming Delayed Price Updated: 3:59 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Organovo Holdings Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis July 16, 2024 From Organovo, Inc. Via GlobeNewswire Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease May 21, 2024 From Organovo, Inc. Via GlobeNewswire Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) May 14, 2024 Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024 From Organovo, Inc. Via GlobeNewswire Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering May 08, 2024 From Organovo, Inc. Via GlobeNewswire Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo April 15, 2024 From Organovo, Inc. Via GlobeNewswire Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress January 25, 2024 From Organovo, Inc. Via GlobeNewswire Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress January 09, 2024 From Organovo, Inc. Via GlobeNewswire Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results December 06, 2023 From Organovo, Inc. Via GlobeNewswire CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan November 13, 2023 From Organovo, Inc. Via GlobeNewswire Organovo Highlights FXR314 Combination Therapy Potential and Plan November 08, 2023 From Organovo, Inc. Via GlobeNewswire Organovo to Participate in the H.C. Wainwright Global Investment Conference September 08, 2023 From Organovo, Inc. Via GlobeNewswire Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data August 23, 2023 From Organovo, Inc. Via GlobeNewswire Organovo Announces FXR Program March 21, 2023 Lead Molecule Poised for Phase 2 in IBD From Organovo, Inc. Via GlobeNewswire Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates November 15, 2022 From Organovo, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.